[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-impairment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-impairment":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,194,0,25,[9,48,82,113,143,169,200,232,261,291,312,343,372,399,423,458,489,512,535,556,586,619,647,674,697],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100445527","a-primary-care-based-psychosocial-intervention-to-improve-cognitive--depression-outcomes-in-older-adults-with-mci--early-stage-ad-100445527",false,"NCT05081596","A Primary Care-Based Psychosocial Intervention To Improve Cognitive & Depression Outcomes in Older Adults With MCI & Early Stage AD","PATH-Pain: A Primary Care-Based Psychosocial Intervention To Improve Cognitive and Depression Outcomes in Older Adults With MCI and Early Stage AD","PATH-Pain","Inclusion Criteria:\n\n* Age ≥ 60 years old\n* MCI or early stage probable or possible AD diagnosis (as defined by Albert et al or McKhann et al) al). Patients will have at least mild cognitive deficits defined by 16 ≤ MoCA ≤ 25.\n* Montgomery Asberg Depression Rating Scale (MADRS)\\[55\\] total ≥ 5, which reflects at least some mild depressive symptoms.\n* Participants will be off antidepressants, cholinesterase inhibitors or memantine or on a stable dosage for at least 12 weeks.\n* Chronic pain (neuropathic, nociceptive or mixed disorders): presence of pain on most days for at least 3 months and average pain intensity score \\>=4.\n* Clinical Dementia Rating 0.5 ≤ (CDR) ≤ 1.\n* Participant will have capacity to consent.\n* Participation of a study partner (e.g. caregiver\u002Ffamily member\u002Fsignificant other) is required.\n\nExclusion Criteria:\n\n* Deemed to have a significant suicide risk as assessed by site PI and clinical team.\n* Deemed too unstable medically or neurologically to safely enroll in a research trial.\n* Deemed too psychiatrically unstable to safely enroll in randomized trial of psychotherapy.\n* Requiring psychiatric hospitalization at baseline for safety.\n* Lack of English fluency.","ALL","60 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of the study is to examine the effect of Problem Adaptation Therapy for Pain (PATH-Pain) on cognitive functioning, depression and pain-related disability in 100 older adults with cognitive impairment, chronic pain, and depression. The study will test if PATH-Pain has better cognitive, affective, and functional outcomes than Attention Control Usual Care.",[28,29,30],"Depression","Pain","Cognitive Impairment",[32,33,34],"Older Adults","Mild Cognitive Impairment","Early Stage Alzheimer's Disease","RECRUITING","2026-08-17",{"date":38,"type":39},"2026-08-20","ACTUAL",{"date":41,"type":39},"2022-06-03",{"date":43,"type":22},"2027-07-31",{"name":45,"class":46},"Weill Medical College of Cornell University","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":68,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":47},"100440369","cognitive-impairment-in-colorectal-cancer-patients-receiving-cytotoxic-chemotherapy-100440369","NCT05014399","Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy","Chemo Brain","Inclusion Criteria:\n\n* Signed written informed consent must be obtained and documented according to International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the local regulatory requirements, and permission to use private health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA) prior to study-specific screening procedures. Must be able to provide study-specific informed consent prior to study entry.\n* A histologically-confirmed colorectal tumor\n* Patients who will be treated with cytotoxic chemotherapies including Capecitabine, Oxaliplatin, 5 fluorouracil, and Irinotecan are eligible.\n* Patients must not have received cytotoxic chemotherapy previous to enrollment.\n\nExclusion Criteria:\n\n* Prior administration of anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents\n* Patients having mental incompetence as assessed by study PI, which would hinder completion of the surveys\n* Pregnant or breastfeeding\n* Any known brain metastases\n* Non-English speaking patients\n* Patients who have been diagnosed with any neuro-cognitive disorder including traumatic brain injuries, Alzheimer's disease, Parkinson's disease, Huntington's disease, and Creutzfeldt-Jakob disease.\n* Patients deemed inappropriate to participate in this study by the study PI or coordinator will be excluded.","18 Years",{"count":57,"type":22},60,"OBSERVATIONAL","The purpose of this research study is to see how the brain changes in patients receiving chemotherapy (cytotoxic drug) treatment for colon or rectal cancer at Parkview Cancer Institute. This information will be used to identify helpful tests to diagnose individuals at risk for developing difficulties with thinking and memory due to their cancer treatments.",[61,30,62,63,64,65,66,67],"Neoplasm, Colorectal","Cognitive Dysfunction","Cognitive Change","Chemo-brain","Chemo Fog","Chemotherapy Effect","Cognitive Decline",[69,70,71,72,30,53],"Palliative Care","Palliative Oncology","Supportive Care","Supportive Oncology","2026-08-13",{"date":75,"type":39},"2026-08-14",{"date":77,"type":39},"2021-09-20",{"date":79,"type":22},"2031-10",{"name":81,"class":46},"Joseph McCollom",{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":100,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":47},"100633163","mecfs-brain-fog-cognitive-rehabilitation-trial-100633163","NCT07523113","ME\u002FCFS Brain Fog: Cognitive Rehabilitation Trial","Brain Training for Chronic, Post-viral, Brain Fog: Study A","Inclusion Criteria:\n\n* diagnosis of ME\u002FCFS that preceded cognitive complaints\n* mild or greater cognitive impairment\n* moderate or greater brain fog\n* some impairment in the performance of daily activities\n* ≥ 18 years, no upper limit if medically stable\n* reside in the community (as opposed to a hospital or skilled nursing facility)\n* able to travel to the laboratory on multiple occasions\n* has Internet service\n* has a personal computer, laptop, or tablet that can access the Internet\n* sufficiently fit, from both a physical and mental health perspective, to take part in the study\n* adequate sight and hearing to complete the UFOV test\n* adequate thinking skills, e.g., ability to follow directions and retain information to complete UFOV and CTAL, as marked by the judgement of the screener that the candidate is able to adequately complete the UFOV and CTAL\n* sufficient English proficiency (i.e., ability to speak, understand, read, and write to take part in study activities)\n\nExclusion Criteria:\n\n* cognitive impairment due to a developmental disability, psychiatric disorder, or substance abuse, or due to another type of brain injury, such as traumatic brain injury, stroke, or a progressive brain disease, such as Alzheimer's Dementia\n* current substance abuse disorder\n* diagnosis of postural orthostatic tachycardia syndrome (POTS) by a healthcare provider\n* prior cognitive processing speed training on DoubleDecision or a similar program\n* cannot tolerate taVNS\n* prior history of heart attack or other serious cardiac events\n* implanted medical device of any type\n* vasovagal syncope or history of fainting\n* history of seizures or epilepsy\n* temporomandibular Joint (TMJ) syndrome or other conditions that cause substantial jaw pain\n* history of peripheral nerve injury to the head, neck, or face\n* pregnant or breastfeeding\n* not able or willing to get an MRI scan\n* not able or willing to get a blood draw",{"count":90,"type":22},30,[25],"The purpose of this study is to compare two approaches to cognitive rehabilitation in adults with post-viral cognitive syndrome, which resulted in brain fog. All participants will be screened for eligibility prior to participation. Most of the procedures will take place over a phone call or secure telehealth platform (i.e., Zoom). However, participants will be asked to visit UAB on three occasions for blood sample collection and brain imaging (about 2 hours each). Online testing will happen one month before treatment, one day before treatment, one day afterwards, and 6 months afterwards. The study will utilize two different forms of rehabilitation training to improve participants' cognitive ability. Participants will be randomized to one of the two treatment groups. The first treatment approach, known as Constraint-Induced Cognitive Therapy (CICT), will feature (A) web-based computer \"games\" that trains how quickly individuals process information that they receive through their senses; (B) online training on everyday activities with important cognitive components, (C) procedures designed to transfer improvements in cognition from the treatment setting to everyday life, and (D) a non-invasive form of vagus nerve stimulation, also known as trans-auricular VNS (taVNS). The second approach, known as Brain Fitness Training (BFT), will include (A) web-based computer \"games\" that train reaction time and eye-hand coordination; (B) in-lab training on relaxation, breathing, healthy nutrition, and healthy sleep, (C) education about how relaxation, breathing, nutrition, and sleep are connected to thinking effectiveness, and (D) taVNS. Approximately 30 hours of training will be conducted over a secure telehealth platform (i.e., Zoom) in the span of two- to four- weeks. A typical CICT session will consist of one hour of gaming, with the bulk of the session being spent on cognitive training of the target behaviors and procedures designed to promote transfer of therapeutic gains to daily life. ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. A typical BFT session will consist of one hour of gaming, training on healthy lifestyle behaviors (i.e., healthy sleep, nutrition, and relaxation habits), as well as procedures designed to promote transfer of behavior changes to daily life. Ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. Training sessions in both conditions will be scheduled based on participants' availability, with the options for sessions scheduled to be as close as every weekday over 2 weeks or as loosely as every other weekday (i.e., over a 4-week span). If a caregiver is available, they will receive training on how to best support participants in their therapeutic program. After the training ends, both groups will receive 4 follow-up phone calls approximately one week apart to promote integration of the gained skills into everyday life. Outcomes measured will include cognitive processing speed, cognitive function on laboratory tests, and spontaneous performance of everyday activities with important cognitive components in daily life.",[94,95,96,97,98,99,30,62],"ME\u002FCFS","ME\u002FCFS Following EBV-associated Infectious Mononucleosis","ME\u002FCFS Following COVID-19","Chronic Fatigue","Chronic Fatigue Syndrome (CFS)","Brain Fog",[94,97,101,30,62,102,103,104],"Brain fog","post-viral syndrome","Cognitive Rehabilitation","CICT","2026-08-12",{"date":75,"type":39},{"date":108,"type":39},"2026-06-23",{"date":110,"type":22},"2028-06",{"name":112,"class":46},"University of Alabama at Birmingham",{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":121,"sex":18,"minAge":122,"maxAge":4,"enrollmentInfo":123,"targetDuration":124,"studyType":58,"phases":4,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":47},"100550540","multimodal-assesment-of-alzheimer-patients-100550540","NCT06448403","Multimodal Assesment of Alzheimer Patients","Multimodal Assessment of Cognitive Impairment in Alzheimer Patients","MultiAD","Inclusion Criteria:\n\n* MCI and AD according to relevant ICD-criterias.\n* Control cohort is age and gender matched with other cohorts.\n\nExclusion Criteria:\n\n* Uneligibility for any of the planned neuroimagery devices (MRI, EEG)\n* AD diagnosis before the age of 65 (Early-onset AD).\n* Brain tumor\n* Traumtic head injury\n* Earlier neurosurgery\n* Other neyrodegenerative diseases (i.e Parkinson and ALS)\n* Diseases related to inflammation and auto-immunity (i.e MS)",true,"65 Years",{"count":57,"type":22},"5 Years","The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD).\n\nThe main questions the study aims to answer are:\n\n1. What findings can be used to earlier detect patients that will develop Alzheimers?\n2. Which differences are seen between healthy and cognitively impaired patients?\n3. Which differences are seen between patients with Alzheimers disease?\n\nParticipants will undergo:\n\n* Cognitive tests\n* Magnetic resonance imaging (MRI)\n* Electroencephalography (EEG)\n* Blood sample collection\n* Fecal sample collection\n* A randomized group will undergo polysomnography analysis.",[33,127,30,128],"Alzheimer Disease, Late Onset","Dementia",[130,131,132,133,134,128,135],"Alzheimer Disease (AD)","Mild cognitive impairment (MCI)","Brain Diseases","Nervous System Disorders","Neurodegenerative Diseases","Cognitive impairment",{"date":73,"type":39},{"date":138,"type":39},"2024-07-01",{"date":140,"type":22},"2030-12-29",{"name":142,"class":46},"Norwegian University of Science and Technology",{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":121,"sex":18,"minAge":55,"maxAge":19,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":47},"100543105","phase-1-examining-the-role-of-tolerance-on-dose-dependent-effects-of-acute-thc-on-oculomotor-and-cognitive-performance-100543105","NCT06351540","Examining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance","Inclusion Criteria:\n\n* Inclusion criteria: Healthy non-treatment seeking adults (age 18 to 60, N = 40) who report\n* (a) infrequent cannabis use defined as at least one reported use in the past year with a negative THC urine toxicology at baseline, or\n* (b) report frequent cannabis use defined as \\> 5 days per week for \\> 1 year with a positive THC urine toxicology at baseline.\n\nThese criteria were selected to target individuals with low and high-frequency cannabis use in order to examine the direct effect of tolerance on study outcome measures.\n\nExclusion Criteria:\n\n* (1) meet DSM-V criteria for substance use disorders other than tobacco, cannabis, or caffeine,\n* (2) are currently receiving or interested in immediately receiving behavioral treatment or medication for cannabis cessation,\n* (3) current use of any medications that could affect study outcomes,\n* (4) test positive for drugs of abuse (other than cannabis) and\u002For breath alcohol test at study admission,\n* (5) have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity,\n* (6) are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding,\n* (7) have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g. Prinzmetal's angina), or (8) are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.",{"count":150,"type":22},40,[152],"PHASE1","The purpose of this research is to determine the extent to which oculomotor function accurately detects THC-impairment, if cannabis use experience impacts this detection threshold, and to examine how the oculomotor index corresponds to a measure of sustained attention. A double-blind, placebo-controlled, within-subjects crossover design will be used to examine the dose-effects of THC (0, 5mg, 30mg) on oculomotor performance tasks and a sustained attention task in frequent and infrequent cannabis users. Results from the study will advance the investigators' understanding of the effect of THC and cannabis use frequency on oculomotor function and sustained attention, and will directly inform the validity of the investigators' oculomotor platform for identifying acute THC- induced impairment in frequent and infrequent users.",[155,156,30],"Cannabis Use","Impaired Driving",[158,159,160],"cannabis","THC","impairment","NOT_YET_RECRUITING",{"date":75,"type":39},{"date":164,"type":22},"2026-10-01",{"date":166,"type":22},"2027-07-01",{"name":168,"class":46},"Johns Hopkins University",{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":181,"conditions":182,"keywords":185,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":47},"100609916","improving-self-care-of-caregivers-of-adults-in-homecare-with-heart-failure-and-cognitive-impairment-100609916","NCT07220798","Improving Self-Care of Caregivers of Adults in Homecare With Heart Failure and Cognitive Impairment","Improving Self-Care of Caregivers of Adults in Homecare With Heart Failure and Cognitive Impairment (iCare4Me Homecare)","iCare4Me HC","Inclusion Criteria:\n\n* Patient Inclusion Criteria\n\n  1. Older adults (=\\>50 years of age)\n  2. Enrolled in Home Health Care\n  3. Documented to have HF\n  4. Mild to moderate CI on the BIMS or OASIS items\n  5. Able to provide informed consent\n  6. Able to provide self-report data\n* Caregiver Inclusion Criteria\n\n  1. Adults (=\\>18 years of age)\n  2. Spouse\u002Fpartner\u002Fchild or other informal caregiver living with or in close proximity to the patient\n  3. Caregiver of a home care patient who is currently receiving or recently received services and who has mild to severe cognitive impairment\n  4. Reporting poor self-care on screening (Health Self-Care Neglect scale score =\\>2)\n  5. Reporting poor mental health on screening (screened with the PROMIS Global Mental Health 4a score \\\u003C12)\n  6. Caregiving or supporting the patient at least 8 hours\u002Fweek\n  7. Able to complete the protocol, e.g., adequate vision and hearing, English speaking.\n  8. Able to provide informed consent\n  9. Able to use technology\n\nExclusion Criteria:\n\n* Patient Exclusion Criteria\n\n  1. Dementia (ICD-10 code for dementia)\n  2. Enrolled in hospice\n  3. Non-English speaking\n* Caregiver Exclusion Criteria 1. Non-English speaking","101 Years",{"count":179,"type":22},316,[25],"This RCT design will enroll 256 informal caregivers (spouse\u002Fpartner or child) of HHC patients with HF\u002FCI and 60 patients with HF and mild to moderate CI (60 dyads). After collecting baseline data, we will block randomize the caregivers 1:1 to the ViCCY intervention or comparator group, stratifying randomization by caregiver sex (male\u002Ffemale), relationship (spouse\u002Fpartner or child), and race (white\u002Fother)- factors known to influence caregiving burden, perceived stress, and receptivity to the intervention. We will encourage caregivers to use their own devices but provide tablet devices with wireless network access if needed. The intervention group will receive 10 sessions of ViCCY over 6 months.",[183,30,184],"Heart Failure","Caregiver Burden",[186,187,188,189,190,191],"heart failure","cognitive impairment","caregiver burden","caregiver stress","self-care","dyads","2026-08-10",{"date":105,"type":39},{"date":195,"type":39},"2026-05-28",{"date":197,"type":22},"2030-04-28",{"name":199,"class":46},"Visiting Nurse Service of New York",{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":18,"minAge":208,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":23,"phases":212,"briefSummary":213,"conditions":214,"keywords":217,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":47},"100529458","early-age-related-hearing-loss-investigation-earhli-100529458","NCT06174038","Early Age-Related Hearing Loss Investigation (EARHLI)","Early Age-Related Hearing Loss Investigation (EARHLI): A Randomized Controlled Trial to Assess the Mechanisms Linking Early Age-Related Hearing Loss and Alzheimer's Disease and Related Dementias","EARHLI","Inclusion Criteria:\n\n* Age 55-75 years of age\n* Adult-onset hearing loss of approximately mild to moderate in severity (4-frequency 0.5, 1, 2, 4 kHz pure tone average 20 dB to 55 dB HL in better hearing ear)\n* Aidable hearing loss, defined by word recognition score in quiet ≥ 60% in better hearing ear\n* Amnestic mild cognitive impairment (MCI) defined by Mini-Mental State Exam (MMSE2) score \\>23, Clinical Dementia Rating (CDR) global score equivalent = 0.5, and ADNI3 criteria of Logical Memory II score of ≤6 if 0-7 years of education, ≤9 if 8-15 years, and ≤11 if ≥16 years\n* Availability of a study partner (informant) for the administration of the cognitive screen and the ADCS-Activities of Daily Living-Prevention Instrument (ADCS-ADL-PI)\n* Community-dwelling\n* Fluent in English or Spanish\n* Availability of participant in area for study duration\n\nExclusion Criteria:\n\n* Self-reported congenital hearing loss, known genetic mutation-related hearing loss, or hearing loss onset before middle age (\\\u003C45 years old)\n* Prior dementia diagnosis\n* Reported disability in ≥ 2 activities of daily living (ADLs)\n* Current or previous consistent hearing aid user (such as utilization of hearing aids within the past 6 months beyond brief trials)\n* Unwillingness to wear hearing aids regularly (≥8 hours\u002Fday)\n* Medical contraindications to the use of hearing aids (e.g., actively draining ear)\n* Corrected vision impairment (worse than 20\u002F63 on MNRead Acuity Chart in worse eye)\n* Untreatable conductive hearing loss with air-bone gap \\> 15 dB in two or more contiguous octave frequencies in both ears","55 Years","75 Years",{"count":211,"type":22},150,[25],"Early Age-Related Hearing Loss Investigation (EARHLI) is a single site study that will randomize late middle age adults to either a hearing intervention (including hearing aids) or a health education intervention. Participants will be followed for 1 year. This study will provide information on reducing cognitive decline in those at risk for Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD\u002FADRD).",[215,216,30],"Alzheimer Disease","Hearing Loss",[216,218,219,220,221,222,223,224],"Alzheimer's","Alzheimer","Hearing Aid","Memory Loss","Memory","Audiogram","Cognition",{"date":105,"type":39},{"date":227,"type":39},"2024-08-01",{"date":229,"type":22},"2027-12-31",{"name":231,"class":46},"Columbia University",{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":18,"minAge":208,"maxAge":239,"enrollmentInfo":240,"targetDuration":4,"studyType":23,"phases":242,"briefSummary":243,"conditions":244,"keywords":247,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":47},"100651633","comparative-evaluation-of-immediate-vs-progressive-standing-dual-task-training-in-elderly-with-mild-and-moderate-cognitive-impairment-100651633","NCT07764250","Comparative Evaluation of Immediate vs Progressive Standing Dual Task Training in Elderly With Mild and Moderate Cognitive Impairment","Immediate Versus Progressive-Standing Dual-Task Training: A Comparative Evaluation in Elderly With Mild and Moderate Cognitive Impairment","Inclusion Criteria:\n\nAge ≥55 years Mild or moderate cognitive impairment MoCA 10-25 MMSE 10-23 Able to participate Provides informed consent\n\nExclusion Criteria:\n\nSevere cognitive impairment Severe sensory or musculoskeletal impairments Unstable medical conditions Participation in another intervention study","90 Years",{"count":241,"type":22},96,[25],"older adults with mild and moderate cognitive impairment. compare immediate vs progressive standing dual-task training. assess balance, cognition, executive function, mobility, and quality of life.",[30,245,246],"Cognitive Impairment, Mild","Moderate Cognitive Impairment",[248,249,250,251,252],"CI","MCI","DTT","ISDTT","PSDDT","2026-08-09",{"date":73,"type":39},{"date":256,"type":39},"2026-06-25",{"date":258,"type":22},"2026-08-30",{"name":260,"class":46},"Shifa Tameer-e-Millat University",{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":18,"minAge":122,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":269,"conditions":270,"keywords":275,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":47},"100651507","reliability-in-neurocognitive-telemedicine-screening-ring-100651507","NCT07760545","Reliability In Neurocognitive Telemedicine Screening (RING)","Inclusion Criteria:\n\n1. Patients with age \\>65 at time of listing for pre-operative assessment.\n2. Patients with a conversational understanding of English language.\n3. Patients scheduled for in-person consult with an anaesthesiologist.\n4. Patients awaiting surgery at Vancouver General Hospital or University of British Columbia Hospital.\n\nExclusion Criteria:\n\n1\\. Patients with known cognitive impairment.",{"count":268,"type":22},300,"Perioperative neurocognitive disorders are common after surgery and pre-existing cognitive impairment is an important risk factor. Current guidelines recommend identifying cognitive impairment before surgery; however, screening remains inconsistent, particularly when preoperative assessments are performed remotely.\n\nThis prospective observational diagnostic validation study aims to determine whether a modified Mini-Cog cognitive screening tool administered by telephone can reliably identify cognitive impairment in patients aged 65 years and older undergoing preoperative assessment. Telephone-based modified Mini-Cog results will be compared with standard in-person Mini-Cog assessments to evaluate agreement and feasibility. This study may improve access to preoperative cognitive screening and support optimization of surgical care for older adults.",[30,271,272,273,274],"Preoperative Cognitive Impairment","Perioperative Neurocognitive Disorders","Neurocognitive Function","Cognitive Screening",[276,135,277,278,279,280,281,282],"Perioperative neurocognitive disorders","Preoperative cognitive screening","Cognitive assessment","Mini-Cog","Modified Mini-Cog","Telephone-based cognitive screening","Telemedicine","2026-08-07",{"date":105,"type":39},{"date":286,"type":39},"2023-05-02",{"date":288,"type":22},"2027-01-30",{"name":290,"class":46},"University of British Columbia",{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":298,"enrollmentInfo":299,"targetDuration":4,"studyType":23,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":47},"100454273","tdcs-to-improve-post-stroke-cognitive-impairment-100454273","NCT05195398","TDCS to Improve Post-Stroke Cognitive Impairment","TIPSCI","Inclusion Criteria:\n\n1. Adults (≥18 years) presenting with neurological symptoms due to acute ischemic stroke (symptom onset within the week prior to admission).\n2. Evidence on brain MRI of acute ischemic stroke (imaging negative strokes and TIAs will be excluded).\n3. Native English speaker (by self-report) prior to stroke.\n4. NIHSS \\\u003C8 at initial follow-up visit (approximately 30 days post-stroke).\n5. mRS 0-2 at initial follow-up visit.\n\nExclusion Criteria:\n\n1. Primary intracerebral hemorrhage- as evidenced by blood on head CT or MRI.\n2. Presence of proximal large vessel occlusion.\n3. Cortical exam findings including aphasia or neglect.\n4. Prior report or history of dementia or undertreated psychiatric illness.\n5. Uncorrected hearing or visual loss.\n6. Inability to attend treatment or follow-up sessions.\n7. Inability to travel to College Park (UMD) for MEG recording sessions.\n8. Presence of any of the following that would lead to significant artifact on MEG: cardiac pacemaker, intracranial clips, metal implants or external clips within 10mm of the head, metal implants in the eyes (unlikely given that all patients will have an MRI and criteria are similar).\n9. Claustrophobia, obesity, and\u002For any other reason leading to difficulty staying in the MEG machine for up to 1 hour.","100 Years",{"count":57,"type":22},[25],"The investigators will conduct a randomized, double-blinded, sham-controlled trial of approximately 60 patients with minor stroke and post-stroke mild cognitive impairment (psMCI). Participants will be individually randomized on enrollment using a random number generator to treatment with anodal tDCS + computerized cognitive treatment (CCT) versus sham + CCT (approximately 30 patients in each arm). Clinical evaluation including assessment of cognition will be performed pre- and post-intervention by individuals on the study team blinded to the participant's intervention. Participants will also undergo functional neuroimaging with magnetoencephalography (MEG) pre- and post-intervention (1, 3, and 6 months post-stroke to evaluate for initial and longer-term effects of treatment on cerebral activation patterns and functional connectivity). Neuroimaging and clinical outcomes will be assessed to determine the effect of tDCS versus sham + CCT on psMCI.",[303,304,30],"Stroke","Stroke Sequelae","2026-08-06",{"date":192,"type":39},{"date":308,"type":39},"2022-09-01",{"date":310,"type":22},"2027-08-31",{"name":168,"class":46},{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":18,"minAge":122,"maxAge":239,"enrollmentInfo":320,"targetDuration":4,"studyType":23,"phases":322,"briefSummary":324,"conditions":325,"keywords":327,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":342},"100602581","phase-1-living-independence-through-functional-training-100602581","NCT07125378","Living Independence Through Functional Training","Living Independence Through Functional Training (LIFT): Feasibility of Hybrid Task-Oriented Resistance Exercise Following Home Health Discharge","LIFT","Inclusion Criteria:\n\n* between the ages of 65 and 90 years\n* community-dwelling\n* live within a 50-mile radius of the study site with wireless connectivity in the area\n* mobility limitations as indicated by self-reported of using a mobility aid or having unsteady gait or walking slower than before\n* cognitive decline as indicated by a score \\\u003C 12 on Mini MoCA Version 2.1\n* a care partner or adult family member living in the home or nearby\n* willing to wear an activity tracker during the study period\n\nExclusion Criteria:\n\n* plan to receive skilled rehabilitation services\n* plan to move away outside the study area in two months\n* reside in an assisted living or long-term care facility or plan to relocate to such a facility in the next three months\n* severe vision or hearing loss that impedes activity performance or communication\n* unable to stand or walk even with a mobility aid\n* unable to follow a one-step command or carry on a conversation over the phone\n* unable to commit to the six-week exercise program\n* contradictions to resistance exercise, such as the end-stage heart failure\n* a terminal disease or on hospice care\n* a neurological condition affecting motor skills\n* not able to provide consent.",{"count":321,"type":22},15,[152,323],"PHASE2","The purpose of the research is to evaluate the feasibility and benefits of a six-week hybrid task-oriented resistance exercise program for older adults who have been recently discharged from home health care.",[326,30],"Mobility Limitation",[328,329,330,331,332,224],"Home-based intervention","Exercise","Older adults","Activities of daily living","Mobility","2026-07-30",{"date":335,"type":39},"2026-07-31",{"date":337,"type":39},"2026-01-06",{"date":339,"type":22},"2026-12-31",{"name":341,"class":46},"University of Florida",2,{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":23,"phases":353,"briefSummary":354,"conditions":355,"keywords":357,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":371},"100649236","early-cognitive-interventions-in-digital-format-for-cancer-survivors-100649236","NCT07729969","Early Cognitive Interventions in Digital Format for Cancer Survivors","Early Cognitive Interventions in Digital Format for Cancer Survivors - INCOTEM","INCOTEM","Inclusion Criteria:\n\n* Patients over 18 years of age diagnosed with cancer (stage I-III)\n* Subjective complaints of cognitive functioning related to the diagnosis of cancer and\u002For cancer treatments\n* Between 1-6 months after completion of chemotherapy treatment\n* To have Wi-Fi and a computer\u002Ftablet\n* To sign the informed consent form\n\nExclusion Criteria:\n\n* Previous history of cancer diagnosis\n* Anticipated change in cancer treatment\u002Fgeneral medical treatment during the intervention period\n* Previous diagnosis of cognitive impairment\n* Diagnosis of other neurological or psychiatric diseases\n* Diagnosis of severe untreated depression\n* History of episodes of vertigo, epilepsy or seizures\n* Currently undergoing or having undergone any other type of intervention aimed at improving cognitive functioning (e.g., CRCI workshops)\n* Severe visual or hearing difficulties that may affect the performance of the intervention exercises\n* Inability to speak, understand, read, and write Spanish correctly\n* Failure to sign the informed consent form",{"count":352,"type":22},110,[25],"The aim of this study is to evaluate the usability and effectiveness of two professionally supervised home-based cognitive training interventions as part of an early rehabilitation protocol for cancer-related cognitive impairment.\n\nParticipants will be randomized to one of the two intervention arms (computerized cognitive intervention or virtual reality cognitive intervention) or to the control group. Participants of the intervention groups will be assessed before and after the 10 weeks intervention or at equivalent time points for the control group. Comparisons between experimental and control participants, and between the participants in the two intervention arms, will be carried out to see which intervention is most effective and accepted.",[30,63,356],"Cancer",[358,359,360,361],"Cancer Related Cognitive Impairment (CRCI)","Digital interventions","Computerized Cognitive Training","Virtual Reality Cognitive Training (VR)","2026-07-22",{"date":364,"type":39},"2026-07-28",{"date":366,"type":39},"2026-06-08",{"date":368,"type":22},"2028-04-30",{"name":370,"class":46},"Biogipuzkoa Health Research Institute",3,{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":18,"minAge":380,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":383,"conditions":384,"keywords":386,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":47},"100601743","delirium-and-cognitive-impairment-development-in-hospitalized-older-adults-under-isolation-conditions-100601743","NCT07114458","Delirium and Cognitive Impairment Development in Hospitalized Older Adults Under Isolation Conditions","Delirium Incidence and Cognitive Trajectories in Isolated Older Patients in the Inpatient Setting","DELiso","Inclusion Criteria: - hospitalized patients\n\n* under isolation precautions for at least 24h\n* 70 years and above\n\nExclusion Criteria: - no informed consent\n\n* intensive care treatment\n* life expectancy 14 days or less","70 Years",{"count":382,"type":22},404,"The goal of this observational study is to examine if older patients who need to be under isolation precautions due to multidrug resistant bacteria or other reasons have an increased risk of suffering from delirium or cognitive decline compared to older patients without isolation precautions.\n\nTo compare this, every person under isolation precautions is compared to other persons of the same age, gender, comorbidities, frailty status and hospital department. Delirium is assessed twice daily with a screening tool named 3D-CAM and cognitive performance is tested by the MOCA-Test six weeks after discharge from hospital and compared to baseline values which are assessed directly after study enrollment.\n\nThe study duration for each patient participating is from the time of enrollment during hospitalization until 6 weeks after hospital discharge.",[385,128,30],"Delirium",[385,387,388,389],"neurocognitive disorder","older adult","isolation precautions","2026-07-21",{"date":392,"type":39},"2026-07-23",{"date":394,"type":39},"2025-08-05",{"date":396,"type":22},"2027-11",{"name":398,"class":46},"Universitätsklinikum Hamburg-Eppendorf",{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":408,"conditions":409,"keywords":412,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":47},"100648459","structural-and-clinical-predictors-of-cognitive-impairment-after-surgical-treatment-for-ruptured-cerebral-aneurysms-100648459","NCT07723131","Structural and Clinical Predictors of Cognitive Impairment After Surgical Treatment for Ruptured Cerebral Aneurysms","Structural and Clinical Predictors of Late Cognitive Impairment After Microsurgical Clipping of Ruptured Cerebral Aneurysms: A Retrospective Cohort With Prospective Assessment","SCOPE-aSAH","Inclusion Criteria:\n\n* Age ≥18 years at the time of aSAH.\n* Treatment by microsurgical clipping of a ruptured cerebral aneurysm.\n* Survival until study recruitment.\n* Ability to understand and sign informed consent.\n\nExclusion Criteria:\n\n* Non-aneurysmal subarachnoid hemorrhage.\n* Exclusively endovascular treatment.\n* Previous diagnosis of dementia.\n* Severe neurological or psychiatric disorders unrelated to aSAH with significant cognitive impact.\n* Absolute contraindication to MRI.\n* Severe aphasia preventing adequate neuropsychological evaluation.\n* Incomplete clinical data.\n* Inability to attend in-person assessment.",{"count":211,"type":22},"This study investigates the clinical and structural predictors of long-term cognitive impairment in patients who underwent microsurgical clipping for aneurysmal subarachnoid hemorrhage. Using a retrospective cohort with prospective neuropsychological and MRI assessments, it aims to identify factors associated with late cognitive deficits and improve prognostic stratification, rehabilitation planning, and long-term patient care.",[410,411,30],"Subarachnoid Aneurysm Hemorrhage","Microsurgery",[413,414,30],"Aneurysmal Subarachnoid Hemorrhage","Aneurysm Clipping","2026-07-20",{"date":392,"type":39},{"date":418,"type":22},"2026-08",{"date":420,"type":22},"2029-12",{"name":422,"class":46},"University of Campinas, Brazil",{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":429,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":18,"minAge":431,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":434,"conditions":435,"keywords":437,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":47},"100648037","blood-tests-for-alzheimers-disease-can-plasma-biomarkers-diagnose-and-predict-disease-progression-100648037","NCT07717567","Blood Tests for Alzheimer's Disease: Can Plasma Biomarkers Diagnose and Predict Disease Progression","The Diagnostic and Prognostic Role of Plasma Biomarkers in Alzheimer's Disease","BLAD","Inclusion Criteria (main study and sub-study):\n\n1. Age greater than or equal to 40 years (patients of childbearing age are admitted).\n2. Subjective or objective cognitive complaints, progressive in nature and of suspected neurodegenerative origin.\n3. Mini-Mental State Examination (MMSE) score greater than or equal to 18.\n\n   Additional inclusion criterion for the validation sub-study:\n4. Availability of CSF biomarkers for Alzheimer's disease within 6 months of the blood draw.\n\nExclusion Criteria (main study):\n\n1. Secondary forms of cognitive impairment based on medical history, neurological examination, and neuroimaging findings.\n2. Pregnancy or breastfeeding.\n3. Rapidly progressive cognitive decline occurring over weeks or months, typically indicative of prion disease, neoplasia, or metabolic disorders.\n4. Subjects who require a legal guardian or tutor.\n\nExclusion Criteria (validation sub-study):\n\n1. Secondary forms of cognitive impairment based on medical history, neurological examination, and neuroimaging findings.\n2. Pregnancy.\n3. Rapidly progressive cognitive decline occurring over weeks or months, typically indicative of prion disease, neoplasia, or metabolic disorders.\n4. Subjects who are unable to give informed consent and require a legal guardian or tutor.","40 Years",{"count":433,"type":22},2000,"BLAD is a prospective, monocentric, observational epidemiological study with an additional procedure (annual blood draw) evaluating the diagnostic and prognostic performance of plasma biomarkers for Alzheimer's disease (AD) in a large cohort of patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital, Milan, Italy.\n\n2000 patients will be enrolled and followed annually for 5 years. A validation sub-study (150 patients) will compare plasma biomarkers against CSF biomarkers as the gold standard.\n\nThe study aims to establish plasma biomarkers as a less invasive and more cost-effective alternative to CSF analysis and amyloid-PET for the diagnosis and prognosis of AD.",[215,33,436,128,30],"Subjective Cognitive Decline",[438,439,440,441,442,443,444,445,446,33,436,128,447,448,449],"Alzheimer's disease","Plasma biomarkers","pTau-181","Abeta42","Abeta40","NfL","GFAP","sTREM2","ApoE","Blood biomarkers","Diagnostic accuracy","Prognosis","2026-07-16",{"date":390,"type":39},{"date":453,"type":39},"2023-09-12",{"date":455,"type":22},"2032-06-01",{"name":457,"class":46},"IRCCS San Raffaele",{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":121,"sex":18,"minAge":55,"maxAge":209,"enrollmentInfo":465,"targetDuration":4,"studyType":23,"phases":467,"briefSummary":468,"conditions":469,"keywords":472,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":47},"100648025","feasibility-and-acceptability-of-stimolirpinia-for-cognitive-rehabilitation-after-severe-acquired-brain-injury-100648025","NCT07718321","Feasibility and Acceptability of StimolIrpinia for Cognitive Rehabilitation After Severe Acquired Brain Injury","StimolIrpinia","Patients With Severe Acquired Brain Injury - Inclusion Criteria\n\n* Age between 18 and 75 years.\n* Level of Cognitive Functioning (LCF) score \\>= 5 at study entry.\n* Stable clinical diagnosis, assessed by at least four repeated LCF evaluations within a 1-week time window.\n* History of severe acquired brain injury of traumatic, anoxic, vascular, or mixed etiology, defined as Glasgow Coma Scale score \\\u003C= 8 for at least 24 hours after brain injury.\n* Pathological performance on at least one Oxford Cognitive Screening (OCS) subscale.\n* Having lived for a prolonged period in the Irpinia area, including Partenio, Valle Ufita-Baronia, Serinese-Solofrana, Alta Irpinia, Vallo di Lauro-Baianese, and\u002For Terminio-Cervialto.\n* Written informed consent signed by the patient or by the patient's legal representative.\n\nPatients With Severe Acquired Brain Injury - Exclusion Criteria • Severe medical conditions that may prevent participation in rehabilitation sessions, including severe language deficits incompatible with understanding instructions, severe cardiovascular instability, photosensitive or reflex epilepsy, and disabling visual or hearing deficits.\n\nRehabilitation Professionals\u002FOperators - Inclusion Criteria\n\n* Age \\>= 18 years.\n* Proven experience in neuromotor and\u002For cognitive rehabilitation of patients with severe acquired brain injury.\n* Written informed consent to participate in the study.\n\nRehabilitation Professionals\u002FOperators - Exclusion Criteria\n\n• Participation in the development of the StimolIrpinia repository, resulting in prior familiarity with the repository.",{"count":466,"type":22},10,[25],"This single-center pilot study evaluates the feasibility, acceptability, usability, and preliminary stimulus validation of StimolIrpinia, a multimedia repository of culturally and territorially relevant autobiographical stimuli designed to support cognitive rehabilitation activities in patients with severe acquired brain injury (sABI). The repository includes images, videos, maps, local cultural information, and printable materials related to the Irpinia area in Campania, Italy. Healthy adult volunteers will review the stimuli for their ability to evoke autobiographical memories, familiarity, emotional activation, and pleasantness. Hospitalized patients with sABI will complete six 30-minute StimolIrpinia-supported rehabilitation sessions over two weeks in addition to their routine comprehensive rehabilitation program. Rehabilitation professionals will receive standardized training and will use the repository to personalize cognitive rehabilitation exercises. Usability and acceptability will be evaluated from both patient and operator perspectives.",[470,30,103,471],"Severe Acquired Brain Injury","Neurorehabilitation",[473,474,475,476,477,478,479,480,481],"severe acquired brain injury","cognitive rehabilitation","ecological rehabiliation","autobiographical stimuli","multimedia repository","acceptability","usability","feasibility","irpinia",{"date":390,"type":39},{"date":484,"type":39},"2026-06-22",{"date":486,"type":22},"2027-08-22",{"name":488,"class":46},"Alfonso Magliacano",{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":18,"minAge":496,"maxAge":239,"enrollmentInfo":497,"targetDuration":4,"studyType":23,"phases":499,"briefSummary":500,"conditions":501,"keywords":502,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":509,"leadSponsor":510,"locationsCount":47},"100635025","effects-of-accelerated-rtms-on-cognitive-function-100635025","NCT07547319","Effects of Accelerated rTMS on Cognitive Function","Clinical and Neurophysiological Effects of Accelerated rTMS on Cognitive Function: A Prospective Pilot Study","Inclusion Criteria:\n\nEach potential subject must satisfy all of the following criteria to be enrolled in the study:\n\n* Subject must be 50 to 90 years of age, inclusive, on the day of signing informed consent.\n* Documented cognitive function decline, defined as:\n\nMoCA score of 10 to 25, inclusive (indicating mild to moderate cognitive impairment), OR Clinical diagnosis of mild cognitive impairment (MCI) or mild dementia based on established DSM-5 diagnostic criteria.\n\n* Ability to provide written informed consent, or availability of a legally authorized representative to provide consent.\n* Subject must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.\n* Sufficient visual and auditory acuity to complete cognitive assessments.\n* Stable doses of any cognitive-enhancing medications (e.g., cholinesterase inhibitors, memantine) for at least 4 weeks prior to screening, with no anticipated changes during the study period.\n* Availability and willingness to complete all scheduled study visits.\n* Presence of a reliable study partner or caregiver who can provide information about the participant's cognitive and functional status.\n* Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the right thumb.\n* Subjects willing and able to abstain from partaking in any treatments other than the study procedure for the improvement in cognitive function, including non-invasive brain stimulation treatments other than the study procedure during study participation.\n* Subjects willing and able to maintain their regular (pre-procedure) diet and exercise regimen without affecting significant change in either direction during study participation.\n* Willingness to comply with study instructions and to return to the clinic for the required visits.\n* Women of child-bearing potential are required to use birth control measures during the whole duration of the study.\n\nExclusion Criteria:\n\nAny potential subject who meets any of the following criteria will be excluded from participating in the study:\n\n* Electronic implants in or near the head - rTMS devices are contraindicated for use in patients who have active or inactive implants in or near the head including device leads, deep brain stimulators, cochlear implants, ocular implants, and vagus nerve stimulators, implanted devices such as cardiac pacemakers, defibrillators, and neurostimulators.\n* Metallic, ferromagnetic, or other magnetic-sensitive implants\u002Fobjects in or near the head - rTMS devices are contraindicated for use in patients who have conductive, ferromagnetic, or other magnetic-sensitive metals implanted in their head (with some exceptions in the mouth - see Operator's Manual) or within 12 inches (30 cm) of the therapy coil. Examples include implanted electrodes\u002Fstimulators, aneurysm clips or coils, stents, bullet fragments, jewelry, hair barrettes, and tattoos with metallic ink.\n* Drug pumps within 12 inches (30 cm) of the therapy coil.\n* Inability to determine the motor threshold of the participant (i.e., the minimum stimulus required to induce contraction of the right thumb cannot be established).\n* History of seizure disorder or epilepsy, except for a single remote seizure more than 5 years ago, which may be permitted at investigator discretion.\n* Elevated risk of seizure due to traumatic brain injury with loss of consciousness \\>30 minutes within the past 12 months.\n* Current use of medications known to significantly lower seizure threshold (e.g., clozapine, bupropion at doses \\>450 mg\u002Fday, theophylline, high-dose tricyclic antidepressants) or recent dose reduction of anticonvulsant medications or benzodiazepines within 4 weeks of screening.\n* Severe dementia, defined as MoCA score below 10, or inability to follow simple verbal commands or complete basic cognitive assessments.\n* Rapidly progressive dementia (e.g., suspected prion disease, autoimmune encephalitis).\n* Brain tumor, intracranial hemorrhage within the past 12 months, arteriovenous malformation, or increased intracranial pressure.\n* Acute stroke within the past 3 months (stable chronic stroke with cognitive sequelae may be included at investigator discretion).\n* Has a current diagnosis of psychotic disorder, bipolar disorder, or other psychiatric condition that, in the investigator's opinion, would interfere with the subject's ability to participate in the trial.\n* Has a current or recent history of serious suicidal ideation within the past 6 months, corresponding to a positive response on item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS, or a history of suicidal behavior within the past year, as validated by the C-SSRS at screening.\n* History of substance or alcohol use disorder of moderate to severe severity according to DSM-5 criteria within 6 months before screening, or positive test result(s) for drugs of abuse (including opiates, cocaine, cannabinoids, methamphetamines, amphetamines) at screening.\n* Has history of or current clinically significant and\u002For unstable medical condition that could interfere with study participation or pose safety concerns, including but not limited to:\n\nModerate or severe hepatic impairment (Child-Pugh Score ≥7) Severe renal impairment (estimated creatinine clearance below 30 mL\u002Fmin or serum creatinine \\>2 mg\u002FdL) Unstable cardiac, vascular, or pulmonary disease Note: Subjects with chronic but stable, well-controlled conditions may be allowed in the study upon agreement with the investigator.\n\n* Has uncontrolled hypertension (systolic blood pressure \\>160 mm Hg or diastolic blood pressure \\>100 mm Hg, despite diet, exercise, or a stable dose of antihypertensive therapy) at screening. A subject with hypertension may be included if the subject's hypertension has been controlled for at least 3 months prior to screening, and the dosage of any antihypertensive medication has been stable for the past 3 months.\n* Has clinically significant ECG abnormalities at screening, defined as:\n\nQTc interval (Fridericia's formula): ≥450 msec (males); ≥470 msec (females) Evidence of 2nd or 3rd degree atrioventricular block, or 1st degree atrioventricular block with PR interval \\>210 msec Left bundle branch block Features of new ischemia Other clinically important arrhythmia Note: Subjects with right bundle branch block may be allowed provided confirmation that right bundle branch block is not associated with underlying cardiac\u002Flung diseases.\n\n\\- Has a known malignancy or history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that, in the opinion of the investigator, is considered cured with minimal risk of recurrence).\n\nHad clinically significant acute illness within 7 days prior to study rTMS treatment.\n\n\\- Had major surgery (e.g., requiring general anesthesia) within 2 weeks before screening, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study.\n\nNote: Subjects with planned surgical procedures to be conducted under local anesthesia may participate.\n\n* Is pregnant or breastfeeding while enrolled in this study or within 1 month after the last session of study rTMS treatment.\n* Has received an investigational drug or used an invasive investigational medical device within 3 months before screening, or is currently enrolled in an investigational study.\n* Prior treatment with rTMS within 6 months of screening.\n* Subjects willing to partake in any treatments other than the study procedure for the improvement in cognitive function, including non-invasive brain stimulation treatments other than the study procedure, during study participation.\n* Has psychological and\u002For emotional problems which would render the informed consent invalid, or limit the ability of the subject to comply with the study requirements.\n* Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.\n* Is an employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator.\n\nNOTE: Investigators should ensure that all study enrollment criteria have been met at screening. If a subject's clinical status changes after screening but before the first rTMS treatment session such that he or she no longer meets all eligibility criteria, then the subject should be excluded from participation in the study.","50 Years",{"count":498,"type":22},80,[25],"Cognitive impairment, including mild cognitive impairment (MCI) and mild dementia, is a growing public health challenge with limited effective treatment options. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that has shown promise for improving cognitive function, but most studies have used conventional protocols and relied on global screening tools that may not capture domain-specific changes.\n\nThe purpose of this study is to evaluate the efficacy and tolerability of repetitive transcranial magnetic stimulation (rTMS) delivered via the EXOMIND™ device (BTL-699-2) for improving cognitive function in adults aged 50 to 90 years with mild to moderate cognitive impairment. The study asks whether a course of 6 rTMS sessions targeting the left dorsolateral prefrontal cortex, administered twice weekly over approximately 3 weeks, can produce meaningful and sustained improvements in global and domain-specific cognitive function over a 3-month follow-up period.\n\nThis is a single-center, open-label, prospective pilot study enrolling 80 participants with documented cognitive decline (Montreal Cognitive Assessment \\[MoCA\\] score 10-25). Participants will receive 6 sessions of high frequency rTMS (6,300 pulses per session at alternating frequencies of 12, 15, and 18 Hz) over approximately 3 weeks. The primary outcome is the change from baseline in MoCA score at 1-month follow-up. Secondary outcomes include changes in MoCA score at post-treatment and 3-month follow-up, changes in domain-specific cognitive measures (visual spatial working memory, episodic memory, deductive reasoning, mental rotation, verbal short term memory, and attention) assessed by the Creyos cognitive battery, and changes in depressive symptoms measured by the Patient Health Questionnaire-9 (PHQ-9). Assessments are performed at baseline, post treatment, 1-month follow-up, and 3-month follow-up. Total study duration per participant is up to 139 days.",[67,30],[503,504,67,249],"rTMS","ExoMind","2026-07-15",{"date":507,"type":39},"2026-07-17",{"date":505,"type":22},{"date":229,"type":22},{"name":511,"class":46},"San Francisco Neurology and Sleep Center",{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":519,"minAge":55,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":23,"phases":522,"briefSummary":523,"conditions":524,"keywords":526,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":528,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":47},"100402428","phase-1-effect-of-nac-on-preventing-chemo-related-cognitive-impairments-in-ovarian-ca-pts-treated-w-pbt-100402428","NCT04520139","Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W\u002F PBT","Phase I Dose-Escalating and Phase II Dose-Expansion Study of N-Acetyl-Cysteine (NAC) Administration to Ovarian Cancer Patients Receiving Platinum-Based Therapy (PBT) for the Mitigation of Chemotherapy-Related Cognitive Impairment (CRCI)","Inclusion Criteria:\n\nPost-menopausal females (as defined by lack of menstruation for 12 months or status post oophorectomy)\n\n* Histologic or pathologic diagnosis of stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer\n* Eastern Cooperative Oncology Group (ECOG) ≤2\n* Life expectancy \\> 1 year\n* Status post cytoreductive surgery for ovarian cancer or with planned cytoreductive surgery if treated with neoadjuvant chemotherapy\n* Prescribed a minimum of six cycles of platinum-based chemotherapy\n* Adequate organ function as defined below:\n\n  1. Hemoglobin \\> 9 g\u002FdL\n  2. Leukocytes \\>1,500\u002Fmcl\n  3. Absolute Neutrophil Count \\> 1,000\u002FmcL\n  4. Platelets \\> 125,00\u002FmcL\n  5. total bilirubin Within normal institutional limits\n  6. Aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) \\\u003C 2.5 x institutional upper limit of normal\n  7. Serum creatinine \\\u003C 1.5 mg\u002FdL.\n\nExclusion Criteria:\n\n* Prior history of any cancer (other than non-melanoma skin cancer)\n* Chemotherapy, radiation therapy, or erythropoietin treatment within the last 6 months\n* Prior severe head injury\n* Has a history of dementia or other neurodegenerative disorders\n* Has an uncontrolled, treatment-resistant depression or other severe psychiatric illnesses\n* Presence of known brain metastases\n* Has an active infection requiring treatment\n* Known immunosuppressive disease\n* Has active systemic autoimmune diseases such as lupus\n* Receipt of systemic immunosuppressive therapy\n* Known human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C\n* Pregnant of breastfeeding.","FEMALE",{"count":521,"type":22},102,[152,323],"This is a phase I, dose-escalation and phase II dose-expansion clinical trial determining the maximum tolerated dose (MTD) and safety and tolerability of adding N-Acetyl-Cysteine (NAC) to ovarian cancer patients who are receiving a platinum-based therapy (PBT). This study will investigate whether NAC will mitigate chemotherapy-related cognitive impairment (CRCI).",[525,30],"Ovarian Cancer",[527],"Chemotherapy-Related Cognitive Impairments",{"date":507,"type":39},{"date":530,"type":39},"2026-05-21",{"date":532,"type":22},"2027-12",{"name":534,"class":46},"University of California, Irvine",{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":18,"minAge":431,"maxAge":209,"enrollmentInfo":542,"targetDuration":4,"studyType":23,"phases":543,"briefSummary":545,"conditions":546,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":47},"100647619","phase-4-efficacy-and-safety-of-canagliflozin-in-the-treatment-of-type-2-diabetes-with-mild-cognitive-impairment-100647619","NCT07711171","Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment","Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment- a Prospective, Randomized, Single-blind, Controlled, Single-center, Head-to-head Clinical Cohort Study","Inclusion Criteria:\n\n* age: 40-75 years old;\n* HbA1c: 7.0 - 10.0%;\n* Moca scale total score between 20-26 (duration of education is more than 10 years) or total score between 20 and 25 (duration of education is less than 10 years);\n* sign informed consent;\n\nExclusion Criteria:\n\n* left-handedness;\n* duration of diabetes is less than 6 years;\n* inability to complete central nervous system magnetic resonance imaging;\n* alcohol or drug addiction history;\n* use of other oral hypoglycemic drugs within 90 days prior to enrollment except for metformin;\n* Family or past history of neurological or psychiatric disorders, pancreatitis, medullary thyroid cancer and multiple endocrine adenomatosis;\n* History of recurrent urinary tract infection and malignant tumor;\n* History of severe gastrointestinal diseases and gastroenteric surgery;\n* Pregnancy\u002Flactation status;\n* Abnormal liver function (liver enzyme index is more than 2.5 times the upper limit of the reference range) or abnormal kidney function (estimated glomerular filtration rate is less than 45ml\u002Fmin); Type 1 diabetes; other diseases or conditions that reduce the possibility of enrollment or complicate enrollment, such as frequent changes in the working environment and unstable living environment, which are likely to cause loss of follow-up, according to the judgment of the researchers;",{"count":57,"type":22},[544],"PHASE4","The prevalence of cognitive dysfunction in diabetic patients is high, which seriously affects the quality of life of patients, and early intervention is of great significance. Central nervous system insulin resistance plays a key role in the pathogenesis of cognitive dysfunction in diabetic patients. Central insulin resistance observed by functional magnetic resonance imaging (fMRI), may serve as an alternative endpoint for assessing cognitive function. Sodium glucose cotransporter 2 inhibitor (SGLT2i) may improve cognitive impairment by improving central insulin resistance.",[547,30],"Type 2 Diabetes Mellitus","2026-07-14",{"date":507,"type":39},{"date":551,"type":39},"2024-08-19",{"date":553,"type":22},"2026-10-30",{"name":555,"class":46},"Fudan University",{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":121,"sex":18,"minAge":563,"maxAge":564,"enrollmentInfo":565,"targetDuration":4,"studyType":23,"phases":567,"briefSummary":568,"conditions":569,"keywords":572,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":4},"100645503","eye-movement-intervention-for-cognitive-impairment-across-schizophrenia-spectrum-100645503","NCT07702526","Eye-Movement Intervention for Cognitive Impairment Across Schizophrenia Spectrum","Effects of an Eye-Movement Intervention on Cognitive Impairment in Individuals Across Illness Stages of Schizophrenia: Protocol for a Stratified Randomized, Active-Controlled, Assessor-Blinded Trial","Inclusion Criteria:\n\n* Age between 15 and 45 years.\n* More than 9 years of education.\n* Normal or corrected-to-normal vision without color blindness, color weakness, strabismus, or nystagmus.\n* Right-handedness.\n* Impaired cognitive performance defined as a T-score \\\u003C40 in at least one MCCB cognitive domain at baseline.\n* Capacity to complete cognitive and eye-tracking assessments.\n* Clinical high-risk group: Meet psychosis-risk syndrome criteria based on SIPS\u002FSOPS, including attenuated positive symptoms or brief intermittent psychotic symptoms.\n* First-episode schizophrenia group: Meet DSM-5 criteria for schizophrenia, with first episode occurring within approximately 2 years of illness onset and minimal prior antipsychotic exposure.\n* Chronic schizophrenia group: Meet DSM-5 criteria for schizophrenia, with illness duration ≥5 years and stable treatment status for the previous 6 months.\n* Healthy control group: No current or past psychiatric disorders based on MINI 7.0 and no significant depressive symptoms based on the Hamilton Depression Rating Scale. Healthy controls will also meet the same general criteria regarding age, education, handedness, and vision.\n\nExclusion Criteria:\n\n* IQ \\\u003C70.\n* Severe or unstable medical or neurological illness (e.g., stroke, epilepsy, dementia, cardiac disease, or uncontrolled hypertension).\n* Substance abuse or dependence.\n* Clinically significant laboratory abnormalities.\n* Visual or auditory impairments affecting task performance.","15 Years","45 Years",{"count":566,"type":22},160,[25],"The goal of this clinical trial is to determine whether a gamified eye-movement intervention can improve cognitive function in individuals across the schizophrenia spectrum, including clinical high-risk individuals, first-episode schizophrenia patients, and chronic schizophrenia patients. The main questions it aims to answer are:\n\n* Does eye-movement training improve cognitive performance measured by the MATRICS Consensus Cognitive Battery (MCCB)?\n* Does eye-movement training improve oculomotor functions and clinical symptoms across different illness stages?\n\nResearchers will compare an eye-movement intervention group with an active control group receiving matched finger-controlled game training to determine whether the eye-movement intervention produces greater improvements in cognitive function and eye-movement performance.\n\nParticipants will:\n\n* Receive either gamified eye-movement training or matched finger-controlled game training for 4 weeks.\n* Complete cognitive assessments using the MCCB before and after the intervention.\n* Complete standardized eye-tracking tasks, including fixation stability, smooth pursuit, antisaccade, and free-viewing tasks, to evaluate changes in oculomotor control and visual exploration patterns.\n* Complete clinical symptom assessments using SOPS or PANSS according to illness stage.",[570,30,571],"Schizophrenia","Clinical High Risk for Psychosis",[573,574,575,576,577],"Eye movement training","Cognitive remediation","BVMT-R","Visuospatial memory","Eye tracking","2026-07-08",{"date":548,"type":39},{"date":581,"type":22},"2026-07-01",{"date":583,"type":22},"2028-07-30",{"name":585,"class":46},"Shanghai Mental Health Center",{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":592,"eligibilityCriteria":593,"healthyVolunteers":121,"sex":18,"minAge":122,"maxAge":4,"enrollmentInfo":594,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":596,"conditions":597,"keywords":601,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":618},"100626159","orthopedic-procedures-and-postoperative-delirium-in-older-adults-in-the-czech-republic-100626159","NCT07432009","Orthopedic Procedures and Postoperative Delirium in Older Adults in the Czech Republic","Orthopedic Procedures and Postoperative Delirium in the Czech Republic","ORTOPODCZ","Inclusion Criteria:\n\n* Age ≥ 65 years\n* Elective total hip arthroplasty in general or regional anesthesia\n* ASA physical status I-III\n* Ability to understand and cooperate during testing; no severe sensory impairment (compensatory aids allowed)\n* Expected postoperative hospitalization in ICU, PACU, or standard ward\n\nExclusion Criteria:\n\n* Glasgow Coma Scale ≤ 14\n* Limited legal capacity\n* Active psychiatric disorder (e.g., psychotic disorder, bipolar disorder)\n* Active oncological disease\n* Chronic use of strong opioids\n* Premedication with anxiolytics or antipsychotics during preanesthetic evaluation\n* Acute reoperation within 3 months of primary surgery\n* Refusal to participate or withdrawal of consent",{"count":595,"type":22},400,"This multicenter, prospective, non-interventional observational study (ORTOPODCZ) investigates the association between preoperative cognitive impairment and postoperative delirium (POD) in older adults undergoing elective total hip arthroplasty in the Czech Republic. Postoperative delirium is a frequent and serious neurocognitive complication in senior surgical patients and is associated with increased morbidity, mortality, prolonged hospitalization, and impaired functional and cognitive outcomes. Despite international recommendations, routine preoperative cognitive screening remains insufficiently implemented.\n\nThe study evaluates the predictive value of the ALBA test, a brief cognitive screening tool, performed during the pre-anesthetic assessment. Postoperative delirium will be assessed using the validated CAM-ICU instrument for up to 72 hours after surgery. Secondary objectives include assessing the relationship between POD and frailty, polypharmacy, comorbidities, type of anesthesia, intraoperative hemodynamics, blood loss, vasoactive support, and postoperative complications.\n\nApproximately 300-400 participants aged ≥65 years will be enrolled across seven centers. No additional procedures, biological sampling, or deviations from standard clinical care are required. Data will be collected in REDCap and analyzed according to a predefined statistical analysis plan. The study aims to provide robust evidence supporting the integration of cognitive screening into routine preoperative evaluation and to describe feasibility and implementation requirements for the ALBA test in clinical practice.",[598,30,32,599,600],"Frailty","Hip Arthroplasty","Postoperative Delirium",[602,603,274,604,272,605,606,607,608,609],"ALBA test","CAM-ICU","Geriatric Patients","Polypharmacy","Clinical Frailty Scale","Total Hip Replacement","Observational Study","Prospective Cohort",{"date":611,"type":39},"2026-07-09",{"date":613,"type":39},"2026-04-24",{"date":615,"type":22},"2030-03-31",{"name":617,"class":46},"Tomas Bata Hospital, Czech Republic",7,{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":623,"acronym":4,"eligibilityCriteria":624,"healthyVolunteers":121,"sex":18,"minAge":55,"maxAge":19,"enrollmentInfo":625,"targetDuration":4,"studyType":23,"phases":627,"briefSummary":628,"conditions":629,"keywords":633,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":342},"100632017","efficacy-of-bright-light-therapy-on-cognitive-impairment-in-major-depressive-disorder-and-its-neuroimaging-mechanisms-protocol-for-a-randomised-controlled-trial-100632017","NCT07508215","Efficacy of Bright Light Therapy on Cognitive Impairment in Major Depressive Disorder and Its Neuroimaging Mechanisms: Protocol for a Randomised Controlled Trial","The inclusion and exclusion criteria for MDD patients. 1、Inclusion Criteria:\n\n1. MDD diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-Ⅳ), first episode or recurrence, confirmed by an experienced psychiatrist using the Mini International Neuropsychiatric Interview.\n2. Age between 18 and 60 years; and gender no-limited;\n3. The severity of MDD symptoms must be ≥14 scores on the HAMD-17;\n4. With CI currently, defined as a total score of \\\u003C70 on the SC;\n5. A SSRI monotherapy at stable dosages for at least 4 weeks; or medication-free status;\n6. Education level above primary school, able to understand and cooperate in completing the study procedures;\n7. Voluntarily participating in this study and sign the informed consent before enrollment.\n\n2、Exclusion Criteria:\n\n1. Current or past diagnosis of any disorder other than MDD according to DSM-Ⅳ criteria;\n2. The scores on the Young Mania Rating Scale (YMRS) are\\>8;\n3. The participants who have undergone other intervention in addition to SSRIs whinin the past 6 months or now, or who plan to do that in 1 month;\n4. The participants with strong self-blame, self-harm, or suicidal risks (the HAMD-17 suicide item score of ≥3);\n5. The participants with severe physical illnesses, including heart failure, renal failure, severe liver dysfunction, hyperthyroidism, or hypothyroidism; Or a history of severe brain trauma or organic brain pathology (e.g., intracerebral hemorrhage, large-area cerebral infarction, encephalitis, epilepsy), as well as neurological diseases;\n6. The participants with any degree of retinal pathology, including retinal dystrophy, age-related macular degeneration, diabetic retinopathy, cataracts, glaucoma, or other ocular diseases;\n7. The participants with photosensitive conditions, such as systemic lupus erythematosus, porphyria, chronic photodermatitis, solar urticaria, or those currently receiving medications that may increase photosensitivity (e.g., phenothiazines, antimalarials, propranolol, hypericin, stimulants, or chronic treatment with nonsteroidal anti-inflammatory drugs);\n8. Pregnant or lactating women;\n9. The participants with contraindications to MRI, such as the presence of non-MRI-safe metallic implants or claustrophobia;\n10. The participants deem unsuitable for inclusion in this study by the investigator for other reasons.\n\nWithdrawal and Termination Criteria：\n\n1. The participants meet one of the exclusion criteria above after enrollment;\n2. When the participants' treatment regimen need change;\n3. The participants who fail to cooperate or voluntarily withdraw from the study;\n4. Due to severe adverse events, the patients are unable to tolerate phototherapy;\n5. The participants who fail to adhere to the study protocol intervention for three consecutive days or for a cumulative duration exceeding seven days;\n6. Cancellation of the study.\n\nThe inclusion and exclusion criteria for Health controls\n\n1\\. Inclusion criteria\n\n1. Age between 18 and 60 years; and gender no-limited;\n2. Without CI currently, defined as a total score of ≤ 70 on the SC;\n3. Education level above primary school, able to understand and cooperate in completing the study procedures;\n4. Voluntarily participating in this study and sign the informed consent before enrollment.\n\n2.Exclusion criteria\n\n1. Current or past diagnosis of any psychiatric disorders, or history of substance\u002Fdrug abuse or dependence;\n2. Current or past diagnosis of severe somatic diseases, such as heart failure, renal failure, severe liver dysfunction, or hyperthyroidism\u002Fhypothyroidism;\n3. History of severe traumatic brain injury or organic brain lesions;\n4. Pregnant or lactating women;\n5. The participants with contraindications to MRI, such as the presence of non-MRI-safe metallic implants or claustrophobia.\n6. The participants deem unsuitable for inclusion in this study by the investigator for other reasons.",{"count":626,"type":22},120,[25],"This study aims to validate the therapeutic efficacy and safety of bright light therapy (BLT) in ameliorating cognitive impairment (CI) in major depressive disorder (MDD), characterize the functional and structural features of the hippocampus (HPC)-dorsolateral prefrontal cortex (dlPFC) neural circuitry in MDD participants with CI and examine the mediating effect of the HPC-dlPFC neural circuit on CI induced by BLT treatment in MDD participants. MDD participants will be required to only receive selective serotonin reuptake inhibitors (SSRIs) as monotherapy for at least four weeks, or medication-free status before enrollment. Eligible participants will be randomly assigned to the experimental group and the control group. The experimental group will receive the intervention of BLT, and the control group will receive the intervention of dim red light (DRL). The intervention will last for four weeks, 6 days per week, with 40 minutes each day between 7 am and 10 am. The MDD participants will be followed once in the end of each week during the 4-week intervention and in the end of the 4th week after intervention. Demographic information will be collected at baseline; cognitive function will be evaluated at baseline, weeks 2, 4, and 8 after intervention beginning; and other symptoms such as depression, anxiety and sleep were assessed at baseline, weeks 1, 2, 3, 4, and 8 after intervention beginning. Moreover, structural and functional MRI scans will be made at baseline and post-intervention. During the intervention, MDD participants will be required to keep a record of daily light exposure duration and complete the daily sleep diary as well.",[630,631,632,30],"Major Depressive Disorder (MDD)","Neuroimaging","Bright Light Treatment",[634,631,635,636,30,637],"Major Depressive Disorder","Magnetic Response Imaging","Bright Light Therapy","Randomized Controlled Trial","2026-07-02",{"date":640,"type":39},"2026-07-06",{"date":642,"type":39},"2026-04-10",{"date":644,"type":22},"2028-12-31",{"name":646,"class":46},"Peking University Sixth Hospital",{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":4,"eligibilityCriteria":653,"healthyVolunteers":12,"sex":18,"minAge":654,"maxAge":655,"enrollmentInfo":656,"targetDuration":4,"studyType":23,"phases":658,"briefSummary":659,"conditions":660,"keywords":664,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":667,"startDateStruct":668,"completionDateStruct":670,"leadSponsor":672,"locationsCount":47},"100610333","phase-1-methylphenidate-to-address-attention-and-executive-deficits-among-children-with-sickle-cell-disease-100610333","NCT07226219","Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease","Pilot Trial of Stimulant Treatment to Address Attention and Executive Deficits Among Children With Sickle Cell Disease","Inclusion Criteria:\n\n* Diagnosed with SCD of any genotype\n* Enrolled on the institutional protocol: Sickle Cell Clinical Research Intervention Program (SCCRIP)\n* Between the ages of 8.0 and 17.9 years\n\n  \\*Included if performance measure, rating scale or diagnostic criteria met (within the past 2 years):\n* \\*Score at or below the 16th percentile on any 2 out of 4 performance measures:\n\n  * NIH Toolbox Flanker\n  * NIH Toolbox List Sorting\n  * NIH Toolbox Dimensional Change Card Sort Test (DCST)\n  * Wechsler Intelligence Scale for Children (WISC) -5\u002F Wechsler Adult Intelligence Scale (WAIS)-4 Digit Span Forward (DSF)\n* \\*Score at or above the 84th percentile on any 1 out of 2 parent rating scales:\n\n  * BRIEF-2 Global Executive\n  * BASC-3 Attention\n* \\*Have a documented diagnosis of attention deficit \u002F hyperactivity disorder (any subtype)\n* English as the primary language\n* Research participant and one parent willing to participate and provide consent\u002Fassent according to institutional guidelines\n* Negative pregnancy test\n\nExclusion Criteria:\n\n* Primary language other than English\n* Score below the 2nd percentile on the Wechsler Abbreviated Scale of Intelligence (WASI)-2 intelligence quotient (IQ) test\n* Uncontrolled seizures (seizure within the past 6 months)\n* Cardiomyopathy or known congenital structural cardiac defects\n* Stenotic valvular disease, left coronary artery stenosis, or history of myocarditis or pericarditis\n* History of heart arrhythmia including ventricular tachycardia, ventricular fibrillation, supraventricular tachycardia, QT prolongation or concomitant use of medications associated with QT prolongation\n* Two or more prior episodes of priapism\n* Blood pressure \\>95th percentile at the three most recent visits consecutively (i.e., \\>95th percentile reading at all three of the most recent hospital visits to St. Jude).\n\n  * If blood pressure is \\> 95th %ile compared to age-norms on the day of the baseline visit, a repeat blood-pressure reading will be performed both electronically and manually to confirm findings.\n* Stimulant medication within the past two weeks\n* Severe sensory loss\n* Previous adverse reaction to methylphenidate\n* Inability or unwillingness of research participant or legal guardian\u002Frepresentative to give written informed consent.\n* Currently prescribed another investigational medication.\n* Currently prescribed any of the following:\n\n  * Phenobarbital (anticonvulsant)\n  * Phenytoin (anticonvulsant)\n  * Primidone (anticonvulsant)\n  * Warfarin (anticoagulant)\n  * Antipsychotic medications\n  * Selective Serotonin Reuptake Inhibitor (SSRI) medications\n  * Tricyclic antidepressant (TCA) medications\n  * Vasopressor medications","8 Years","17 Years",{"count":657,"type":22},72,[152],"The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects.\n\nThe study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not.\n\nPrimary Objective:\n\n• Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits.\n\nSecondary Objective:\n\n• Evaluate neurobehavioral and safety outcomes following MPH treatment.\n\nExploratory Objective:\n\n• Evaluate decision-making and determinants influencing methylphenidate utilization among parents.",[661,662,30,663],"Sickle Cell Disease","Executive Dysfunction","Attention Deficit\u002FHyperactivity Disorder (ADHD)",[665,666],"SCD","ADHD",{"date":640,"type":39},{"date":669,"type":39},"2025-11-25",{"date":671,"type":22},"2028-08-01",{"name":673,"class":46},"St. Jude Children's Research Hospital",{"id":675,"slug":676,"hasResults":12,"nctId":677,"briefTitle":678,"officialTitle":679,"acronym":4,"eligibilityCriteria":680,"healthyVolunteers":121,"sex":519,"minAge":681,"maxAge":122,"enrollmentInfo":682,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":683,"conditions":684,"keywords":686,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":689,"startDateStruct":691,"completionDateStruct":693,"leadSponsor":695,"locationsCount":47},"100385308","brain-health-in-breast-cancer-survivors-100385308","NCT04297020","Brain Health in Breast Cancer Survivors","Brain Health in Breast Cancer Survivors: Interaction of Menopause and Endocrine Therapy","Inclusion Criteria:\n\n* Age 35-65\n* Fluent in English\n* Adequate vision\u002Fhearing to complete testing\n\nExclusion Criteria:\n\n* History of major or mild neurocognitive disorder or dementia\n* Diagnosis of major neurological condition (e.g., epilepsy, Parkinson's Disease, stroke)\n* Diagnosis of a major psychiatric disorder (e.g., bipolar disorder, schizophrenia)\n* Untreated\u002Funstable unipolar depression or anxiety\n* Prior history of cancer or chemotherapy (for controls, any history)\n* History of a learning disorder\n* History of head injury with loss of consciousness \\>20 minutes\n* History of salpingo-oophorectomy or hysterectomy\n* A cardiac pacemaker\n* Implanted electronic device\n* Claustrophobia\n* Currently pregnant\n* Orbital metal implant or other metallic foreign bodies\n\nAdditional exclusion criteria for controls: current use of a contraceptive agent that interferes with endogenous hormonal fluctuation (e.g., oral contraceptive pill) or precludes determination of menstrual pattern (e.g., hormonally secreting intrauterine device), or current treatment with systemic estrogen replacement therapy.","35 Years",{"count":626,"type":22},"Endocrine therapy (ET) is widely used to treat hormone receptor positive breast cancer and prevent recurrence by downregulating estrogen function. However, ETs readily cross the blood brain barrier and interfere with the action of estrogen in the brain. Estrogen supports cognition and menopausal status is closely linked to cognitive health in women. This has raised concern that anti-estrogen ETs may affect cognition and brain health in breast cancer survivors. However, evidence across existing studies is inconsistent and these effects remain poorly understood. The incomplete understanding of the effects of ET are likely due to limitations of earlier studies - namely, the under-appreciation of the role of menopausal status and insensitivity of standard cognitive measures. This research project will address these earlier limitations by specifically comparing ET effects by menopausal status, and using highly sensitive, task-related functional magnetic resonance imaging (fMRI) measures to assess the effects of ET on brain function.",[30,685],"Cognitive Function",[687,688],"Breast cancer","endocrine therapy",{"date":690,"type":39},"2026-07-07",{"date":692,"type":39},"2020-03-11",{"date":694,"type":22},"2028-03-15",{"name":696,"class":46},"Jonsson Comprehensive Cancer Center",{"id":698,"slug":699,"hasResults":12,"nctId":700,"briefTitle":701,"officialTitle":702,"acronym":703,"eligibilityCriteria":704,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":705,"targetDuration":4,"studyType":23,"phases":706,"briefSummary":707,"conditions":708,"keywords":710,"overallStatus":161,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":713,"startDateStruct":714,"completionDateStruct":715,"leadSponsor":716,"locationsCount":47},"100517758","the-care-for-americas-aging-study-100517758","NCT06021704","The Care for America's Aging Study","Care for America's Aging (CfAA): A Study to Improve Behavioral and Quality of Life Outcomes of Older Adults With Cognitive Impairment and Dementia and Their Care Partners","CfAA","Inclusion Criteria for Patients:\n\n* Age 60 years and above\n* Patients in Mass General Brigham healthcare system\n* Mild cognitive impairment or dementia diagnosis of no greater than mild-moderate severity\n* Discharge plan includes referral to home care services\n* As all surveys have been validated in English, we will limit participation to potential participants able to read English.\n\nExclusion Criteria for Patients:\n\n* Discharge to Medicare short-term rehab only\n* Lack of care partner\n* Enrolled in palliative care (projected survival \\\u003C 6 months)\n* Clinical severity of dementia that is moderate or greater\n* Any active clinical issues barring safe participation\n* Montreal Cognitive Assessment (MoCA)-blind score below cutoff\n* University of California, San Diego Brief Assessment of Capacity to Consent (UBACC) score below cutoff",{"count":626,"type":22},[25],"Care for America's Aging is a randomized pilot study investigating whether a home health aide training intervention consisting of enhanced dementia-specific curriculum content will improve: 1) behavioral symptoms of older adult persons living with dementia or cognitive impairment (PLWD\u002FCI) and 2) global health-related quality of life among PLWD\u002FCI and their care partners.",[30,709,128,215],"Dementia With Behavioral Disturbance",[711,712],"Improving Home Care","Enhanced Training for Home Health Aides",{"date":640,"type":39},{"date":164,"type":22},{"date":644,"type":22},{"name":717,"class":46},"Massachusetts General Hospital"]